EMA's recommendation for the French firm's vaccine Ixchiq comes as the mosquito-borne disease, for which no approved drugs exist, has been spreading due to climate change. While environmental conditions in Europe are not yet favorable for chikungunya, the European Centre for Disease Prevention and Control (ECDC) warns of potential risks, citing the influx of potentially infected travelers and a population that could be susceptible to it.